The Power of the Purse: FDA Seeks More Money, Not More Authority
This article was originally published in RPM Report
Executive Summary
Congress can't wait to shower FDA with more regulatory authority, especially in the area of drug safety. But unless Capitol Hill can puts its money where its mouth is, expanding FDA's mission will only send the agency deeper into a fiscal crisis -- and leave industry worse off as a result. An underfunded agency leaves officials scrambling to complete day-to-day activities -- and less time to on activities to further drug development, like nanotechnology and the Critical Path initiative.
You may also be interested in...
Reinforcements At Last: CDER Hiring Process Well Underway
FDA is in the midst of a hiring frenzy to rebuild a severely understaffed agency. The good news is that the center for drugs is about halfway through the process, with the Office of New Drugs receiving the bulk of new hires. It's not equal across review divisions-some are receiving more new people than others.
Reinforcements At Last: CDER Hiring Process Well Underway
FDA is in the midst of a hiring frenzy to rebuild a severely understaffed agency. The good news is that the center for drugs is about halfway through the process, with the Office of New Drugs receiving the bulk of new hires. It's not equal across review divisions-some are receiving more new people than others.
The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability
Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.